Controversies Amidst Progress on CVOTs: You Be the Judge™

The symposium will relate recent ASCVD outcomes trials results and address important controversies arising from them.

Live Meeting
2.00 available credits
Information
November 17, 2019
06:30 PM - 09:00 PM EST
The Ritz Carlton Philadelphia
10 Avenue of the Arts, Grand Ballroom, Philadelphia, Pennsylvania, United States
Controversies Amidst Progress on CVOTs: You Be the Judge™
Choose a format
Details
Presenters
Related
Comments
  • Overview

    This 2-hour, interactive symposium will provide an opportunity for participants to evaluate the potential clinical value of recent large-scale randomized clinical trials on the management of patients at high risk of having atherosclerotic cardiovascular disease (ASCVD) events. Over the past year, many high quality ASCVD outcomes trials have been published, and their impact on clinical management is already taking shape. Amidst this progress in translational science, clinicians have several important issues to address so that the full benefit of the science is realized in clinical management.

    The program will relate these recent ASCVD outcomes trials results and address important controversies arising from them. 

    A rigorous and thorough review of the Level A cardiovascular outcomes trials (CVOTs) will be presented. Additionally, 3 controversial issues will be treated with 2 perspectives by experts on the topics, allowing different points to be emphasized and showing where there may not be unanimity. For each issue, the audience will have the opportunity to decide which expert made the most compelling argument.

    The faculty will consist of internationally recognized experts in CVOTs and CVD risk reduction. The symposium will feature a unique format that is highly interactive, provides multiple perspectives, and allows significant audience participation, with the goal of improving competence and confidence in clinical management.

    This event is not part of the official Scientific Sessions as planned by the AHA Committee on Scientific Sessions Programming.

  • Learning Objectives

    At the conclusion of this activity, learners should be better able to:

    • Discuss the recent cardiovascular outcomes trials results and their clinical implications in reducing ASCVD adverse events
    • Recognize the importance of managing total cardiovascular disease risk beyond lowering LDL-C
    • Apply evidence-based guidelines and recent randomized clinical trial evidence to reduce residual ASCVD risk
  • Agenda

    6:30 PM Registration and Buffet

    7:00 PM Welcome and Opening Remarks
    Roger Blumenthal, MD, Co-Chair; Peter Libby, MD, Co-Chair

    7:10 PM Comprehensive Review of the REDUCE-IT Database
    Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

    7:30 PM Clinical Implications of 2019 Level A CVOTs on CVD Risk Reduction
    Robert H. Eckle, MD

    7:50 PM Panel Discussion, Q&A

    8:00 PM Controversies 1: What is the MOA for EPAs Effect on ASCVD?
    Peter Libby, MD; Preston Mason, PhD

    8:15 PM Controversies 2: What is a Normal TG Level in Patients with CVD?
    Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC; Roger Blumenthal, MD

    8:30 PM Controversies 3: What’s the Optimal Pharmacotherapy Algorithm for Patients with Diabetes to Reduce CVD Risk?
    Robert H. Eckle, MD; P. Gabriel Steg, MD

    8:45 PM Question and Answer

    9:00 PM Adjourn

  • Target Audience

    Cardiovascular healthcare professionals including physicians, nurses, pharmacists who manage patients or work in a health system with relevant issues/challenges in the management of these patients

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Provider(s)/Educational Partner(s)

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • American Disabilities Act

    Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Jessica McGrory prior to the live event at jmcgrory@omnia-prova.com.

Facebook Comments

Details
Presenters
Related
Comments
  • Overview

    This 2-hour, interactive symposium will provide an opportunity for participants to evaluate the potential clinical value of recent large-scale randomized clinical trials on the management of patients at high risk of having atherosclerotic cardiovascular disease (ASCVD) events. Over the past year, many high quality ASCVD outcomes trials have been published, and their impact on clinical management is already taking shape. Amidst this progress in translational science, clinicians have several important issues to address so that the full benefit of the science is realized in clinical management.

    The program will relate these recent ASCVD outcomes trials results and address important controversies arising from them. 

    A rigorous and thorough review of the Level A cardiovascular outcomes trials (CVOTs) will be presented. Additionally, 3 controversial issues will be treated with 2 perspectives by experts on the topics, allowing different points to be emphasized and showing where there may not be unanimity. For each issue, the audience will have the opportunity to decide which expert made the most compelling argument.

    The faculty will consist of internationally recognized experts in CVOTs and CVD risk reduction. The symposium will feature a unique format that is highly interactive, provides multiple perspectives, and allows significant audience participation, with the goal of improving competence and confidence in clinical management.

    This event is not part of the official Scientific Sessions as planned by the AHA Committee on Scientific Sessions Programming.

  • Learning Objectives

    At the conclusion of this activity, learners should be better able to:

    • Discuss the recent cardiovascular outcomes trials results and their clinical implications in reducing ASCVD adverse events
    • Recognize the importance of managing total cardiovascular disease risk beyond lowering LDL-C
    • Apply evidence-based guidelines and recent randomized clinical trial evidence to reduce residual ASCVD risk
  • Agenda

    6:30 PM Registration and Buffet

    7:00 PM Welcome and Opening Remarks
    Roger Blumenthal, MD, Co-Chair; Peter Libby, MD, Co-Chair

    7:10 PM Comprehensive Review of the REDUCE-IT Database
    Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

    7:30 PM Clinical Implications of 2019 Level A CVOTs on CVD Risk Reduction
    Robert H. Eckle, MD

    7:50 PM Panel Discussion, Q&A

    8:00 PM Controversies 1: What is the MOA for EPAs Effect on ASCVD?
    Peter Libby, MD; Preston Mason, PhD

    8:15 PM Controversies 2: What is a Normal TG Level in Patients with CVD?
    Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC; Roger Blumenthal, MD

    8:30 PM Controversies 3: What’s the Optimal Pharmacotherapy Algorithm for Patients with Diabetes to Reduce CVD Risk?
    Robert H. Eckle, MD; P. Gabriel Steg, MD

    8:45 PM Question and Answer

    9:00 PM Adjourn

  • Target Audience

    Cardiovascular healthcare professionals including physicians, nurses, pharmacists who manage patients or work in a health system with relevant issues/challenges in the management of these patients

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Provider(s)/Educational Partner(s)

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • American Disabilities Act

    Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Jessica McGrory prior to the live event at jmcgrory@omnia-prova.com.

Facebook Comments

Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free